Vision 2030: Argenx Aims to Help 50,000 Patients Worldwide

The Belgian biotechnology company Argenx specializes in the development of innovative antibody therapies for autoimmune diseases. The focus is particularly on the drug Vyvgart, which is approved for the treatment of myasthenia gravis and has a promising pipeline for additional indications. Through strategic partnerships and a strong presence in the US market, Argenx has achieved significant growth in recent years. The combination of scientific expertise and a clear focus on rare diseases makes the company an important player in the field of immunotherapy....